Quasi‑insulinoma (Nesidioblastosis) – A Complete Patient Guide
Overview
Quasi‑insulinoma, also called nesidioblastosis, is a rare disorder in which the pancreatic β‑cells (the cells that produce insulin) become over‑active or proliferate abnormally, causing the body to release too much insulin. The result is recurrent or persistent low blood glucose (hypoglycemia), often without a discrete tumor being present.
Who it affects:
- Neonates and infants: Congenital nesidioblastosis is the most common cause of severe hypoglycemia in newborns, affecting roughly 1 in 50,000 live births.[1]
- Children and adolescents: Cases may present after infancy, sometimes triggered by genetic mutations.
- Adults: A much smaller subset (estimated 1–2 per 100,000 adults) develops an acquired form, often after gastric‑by‑pass surgery or certain medications.[2]
Because the condition is uncommon, many patients experience a long diagnostic journey before receiving a definitive diagnosis.
Symptoms
Symptoms stem from low blood glucose and can vary in severity. Recognizing the pattern—especially when symptoms improve after eating—helps differentiate nesidioblastosis from other causes of hypoglycemia.
Typical hypoglycemic symptoms
- Dizziness or light‑headedness – often described as “the room spinning.”
- Palpitations / rapid heart rate – due to adrenaline release.
- Sweating (diaphoresis) – especially on the forehead, palms, and soles.
- Tremor or shakiness – may affect hands or whole body.
- Hunger (hyperphagia) – intense craving for food, sometimes within minutes of a meal.
- Headache – dull or throbbing.
- Blurred vision – temporary trouble focusing.
- Confusion, irritability, or mood changes – can be mistaken for behavioral issues in children.
Severe or neuroglycopenic symptoms (when glucose < 45 mg/dL)
- Slurred speech
- Difficulty concentrating or “brain fog”
- Weakness or clumsiness
- Seizures (particularly in infants)
- Loss of consciousness or fainting (syncope)
- Coma – a medical emergency.
Other clues that point toward quasi‑insulinoma
- Hypoglycemia occurring **fasting** (overnight or >4 h after a meal) or **post‑prandial** (within 1‑3 h after eating).
- Symptoms that resolve quickly after ingestion of glucose or a sugary snack.
- Recurrent episodes despite normal diet and lack of insulin‑or diabetes medication use.
Causes and Risk Factors
Quasi‑insulinoma is not a single disease entity but rather a spectrum of β‑cell dysregulation.
Congenital (genetic) forms
- Activating mutations in the KCNJ11 or ABCC8 genes (encoding the ATP‑sensitive potassium channel) – the most common cause in neonates.[3]
- GLUD1 mutations (hyperinsulinism/hyperammonemia syndrome) – present with both hypoglycemia and elevated ammonia.
- HADH, GCK, and HNF4A mutations – less frequent but documented.
Acquired forms in adults
- Post‑bariatric surgery: After gastric bypass or sleeve gastrectomy, rapid nutrient delivery to the small intestine can trigger exaggerated incretin release (especially GLP‑1), stimulating β‑cells.[4]
- Medications: Sulfonylureas, meglitinides, or β‑cell‑stimulating agents used for diabetes can paradoxically cause persistent insulin secretion if misused.
- Pancreatic islet hyperplasia secondary to endocrine tumors – rare.
Risk factors
- Family history of congenital hyperinsulinism.
- Recent bariatric surgery (especially Roux‑en‑Y gastric bypass).
- Use of insulin secretagogues (e.g., sulfonylureas) without appropriate monitoring.
- Certain metabolic disorders (e.g., fatty‑acid oxidation defects) that indirectly affect β‑cell function.
Diagnosis
Because symptoms overlap with many other conditions, a systematic approach is essential.
1. Confirming true hypoglycemia
- Whipple’s triad: (1) Symptoms of hypoglycemia, (2) documented low plasma glucose < 55 mg/dL (3.0 mmol/L) at the time of symptoms, and (3) relief of symptoms after glucose administration.
- Blood glucose should be measured during an episode using a calibrated glucometer or laboratory sample.
2. Laboratory evaluation during an episode
| Test | Typical finding in nesidioblastosis |
|---|---|
| Plasma insulin | Inappropriately normal or elevated (>3 µU/mL) despite low glucose. |
| C‑peptide | Elevated (reflects endogenous insulin production). |
| Proinsulin | Often increased. |
| Beta‑hydroxybutyrate | Suppressed (insulin inhibits ketogenesis). |
| Growth hormone & cortisol | Usually adequate; helps rule out adrenal insufficiency. |
3. Imaging studies
- Pancreatic MRI or CT scan: Looks for a focal insulinoma; usually negative in nesidioblastosis.
- Endoscopic ultrasound (EUS): High‑resolution; can detect small lesions missed on CT.
- 68Ga‑DOTATATE PET/CT or 18F‑DOPA PET: Useful for locating insulin‑producing tissue, though sensitivity for diffuse disease is limited.
4. Specialized functional tests
- 72‑hour supervised fast: Gold standard to provoke hypoglycemia under controlled conditions. In nesidioblastosis, hypoglycemia often occurs early (within the first 24 h) and is associated with high insulin.
- Selective arterial calcium stimulation (SACS) with hepatic venous sampling: Calcium is injected into pancreatic branches; a rise in insulin indicates hyperfunctioning tissue. Helpful for distinguishing diffuse vs. focal disease before surgery.
5. Genetic testing
If congenital hyperinsulinism is suspected (especially in infants), sequencing of KCNJ11, ABCC8, GLUD1, and related genes is recommended. Results guide therapy (e.g., responsiveness to diazoxide).
Treatment Options
Therapy aims to prevent hypoglycemia while preserving quality of life. Choice depends on age, disease extent (focal vs. diffuse), and underlying cause.
Medical Management
- Diazoxide: First‑line oral agent; opens K‑ATP channels, reducing insulin release. Starting dose 5–15 mg/kg/day divided 3–4 times. Monitor for fluid retention, hirsutism, and liver dysfunction.[5]
- Octreotide (or long‑acting repeatable octreotide – LAR): Somatostatin analog that suppresses insulin secretion. Initial dose 10–20 µg/kg/day subcutaneously; LAR 20–30 mg IM every 28 days for adults. Side effects include gastrointestinal upset, gallstones, and glucose intolerance.
- Everolimus: mTOR inhibitor shown to reduce β‑cell hyperplasia in a few case series. Used off‑label; requires close monitoring of lipids, renal function, and infection risk.
- GLP‑1 receptor antagonists (e.g., exendin (9‑39)): Experimental; may be considered in research protocols.
Surgical Options
- Partial (subtotal) pancreatectomy: Removal of 30–70 % of the pancreas for diffuse disease. Provides long‑term control in ~70 % of patients, but raises the risk of exocrine insufficiency and diabetes.
- Focal lesionectomy: If SACS or imaging identifies a focal area, limited resection can cure the patient while preserving pancreatic tissue.
- Enucleation: Rare; used when a solitary insulinoma is present, not typical for nesidioblastosis.
Nutrition & Lifestyle
- Frequent small meals (every 3–4 h) with a balanced mix of complex carbohydrates, protein, and healthy fats.
- Include a “quick‑carb” snack (e.g., glucose tablets, fruit juice) readily available for emergency treatment.
- Avoid prolonged fasting; limit alcohol, which can blunt gluconeogenesis.
- In adults post‑bariatric surgery, consider a diet low in rapidly absorbable carbs and discuss GLP‑1 antagonist trials with a bariatric specialist.
Living with Quasi‑insulinoma (nesidioblastosis)
Managing a chronic hypoglycemic condition involves both medical vigilance and practical daily strategies.
Monitoring
- Keep a glucose log (paper or app) documenting readings, meals, symptoms, and medication doses.
- For children, a continuous glucose monitor (CGM) can alert caregivers to impending lows.
- Schedule routine labs every 3–6 months: fasting glucose, HbA1c (to ensure no overt hyperglycemia), liver/kidney function, and medication levels if applicable.
Emergency kit
- Glucose gel or tablets (15–20 g glucose per dose).
- A glucagon emergency kit (auto‑injector) for severe episodes when the patient cannot swallow.
- Written emergency plan shared with family, school, or workplace personnel.
Education & Support
- Join patient advocacy groups such as the Hypoglycemia Foundation or a local “Hyperinsulinism Network.”
- Teach school nurses, teachers, and coworkers how to recognize hypoglycemia and use the emergency kit.
- Consider genetic counseling if a hereditary mutation is identified.
Addressing psychosocial impact
Frequent episodes can cause anxiety, especially in children. Cognitive‑behavioral therapy, stress‑management techniques, and regular physical activity (when glucose is stable) improve overall well‑being.
Prevention
Because many cases are genetic, primary prevention is limited. However, certain steps can reduce the risk of developing the acquired adult form:
- Post‑bariatric monitoring: Screen for hypoglycemia 6–12 months after gastric bypass; intervene early if symptoms appear.
- Medication safety: Avoid self‑medicating with sulfonylureas or other secretagogues unless prescribed.
- Pregnancy counseling: Women with known congenital hyperinsulinism should discuss potential risks with a maternal‑fetal medicine specialist.
Complications
If hypoglycemia remains uncontrolled, serious sequelae can develop:
- Neurocognitive impairment: Repeated severe lows in infants and children are linked to learning difficulties, attention deficits, and lower IQ.[6]
- Seizures & status epilepticus.
- Accidents & injuries due to syncope or impaired coordination.
- Pancreatic exocrine insufficiency after extensive pancreatectomy, leading to malabsorption, steatorrhea, and weight loss.
- Secondary diabetes mellitus when enough β‑cell tissue is removed or scarred.
- Psychiatric issues: Anxiety, depression, and fear of eating (avoidance) are common.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Loss of consciousness or fainting.
- Seizure activity (with or without prior known hypoglycemia).
- Persistent confusion or inability to arouse despite carbohydrate intake.
- Rapid heartbeat, shakiness, and sweating that do NOT improve after eating a sugary snack within 5 minutes.
- Signs of severe dehydration (dry mouth, dizziness when standing).
Bring your glucose log, medication list, and emergency kit if possible.
Key Takeaways
- Quasi‑insulinoma (nesidioblastosis) is a rare cause of hyperinsulinemic hypoglycemia, most common in newborns but also seen in adults.
- Prompt recognition of Whipple’s triad and targeted laboratory testing are essential for diagnosis.
- Medical therapy (diazoxide, octreotide) works for many, but surgery may be required for refractory or diffuse disease.
- Living with the condition requires vigilant glucose monitoring, an emergency treatment plan, and multidisciplinary support.
- Uncontrolled hypoglycemia can lead to permanent brain injury; seek emergency care for any severe or prolonged low‑glucose events.
References
- Mayo Clinic. “Congenital hyperinsulinism.” 2023. https://www.mayoclinic.org
- Cleveland Clinic. “Nesidioblastosis (Adult Hyperinsulinism).” 2022.
- NIH Genetic and Rare Diseases Information Center. “Hyperinsulinism, congenital, 2.” 2021.
- American Society for Metabolic and Bariatric Surgery. “Post‑bariatric hypoglycemia.” 2020.
- Diazoxide FDA Label. Accessed May 2024.
- Jenkins R. et al. “Neurocognitive outcomes in children with congenital hyperinsulinism.” *Pediatrics*, 2021;147(3):e2020015321.